

FACTSHEET FY2025



~50
development
projects*



> 400
pharmaceutical
ingredients*



> 1,400
marketing
authorisations*




3,454
employees
worldwide*

* Figures: Status 31 Dec 2025

KEY FIGURES (IFRS)¹

		2025	2024	2023	2022	2021
Revenue	EUR million	1,165.0	1,180.8	1,135.4	1,024.8	942.9
Adjusted EBITDA	EUR million	324.8	315.6	310.2	359.8	351.1
Adjusted EBITDA-margin	%	27.9	26.7	27.3	35.1	37.2
Unadjusted EBITDA	EUR million	317.6	308.9	280.3	331.3	354.4
Unadjusted EBITDA-margin	%	27.3	26.2	24.7	32.3	37.6
Operating income	EUR million	220.7	216.9	182.9	243.7	298.5
Earnings before taxes	EUR million	183.5	172.0	106.0	216.3	293.0
Profit or (loss) for the period	EUR million	131.4	111.7	60.5	132.6	208.9
Earnings per share	EUR	2.46	2.11	1.16	2.49	3.89

DERMAPHARM SHARE IN COMPARISON



Source: Xetra closing prices

COMPANY PROFILE

Dermapharm is a fast-growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the company is based in Grünwald near Munich. In addition to its main site in Sandersdorf-Brehna near Leipzig, Dermapharm operates further production, development and sales sites primarily within Europe and in the USA. Dermapharm employs 3,454 people worldwide as of 31 December 2025.

REASONS TO INVEST

- 01** Clear focus on Europe as a quality location
- 02** High-growth pharmaceutical manufacturer in selected, profitable niche markets
- 03** In-house R&D competence
- 04** Pipeline with ~50 ongoing development projects
- 05** Successful track record in acquisitions
- 06** Expansion of international presence

FINANCIAL CALENDAR 2026

Publication of Q1 Interim Statement	13 May 2026
Annual General Meeting	26 June 2026
Publication of preliminary half-year results for 2026	11 August 2026
Publication of 2026 Half-Year Financial Report	25 August 2026
Publication of Q3 Quarterly Report	12 November 2026

FACTS ABOUT DERMAPHARM SHARE

Ticker symbol	DMP
Ticker Symbol Bloomberg	DMP:GR
Ticker Symbol Reuters	DMPG.DE
WKN	A2GS5D
ISIN	DE000A2GS5D8
Number of shares	53.84 Mio.
IPO	09 February 2018
Stock Exchange	Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

CONTACT

Dermapharm Holding SE
Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 641 86 233, E-Mail: ir@dermapharm.com

NOTICE

This publication contains various statements concerning the future development of the Dermapharm Group. These statements are based on both assumptions and estimates. Our assumptions involve risks and uncertainties that could cause actual results to differ materially from those anticipated. There are no plans to update the forward-looking statements. Throughout this publication, apparent differences may occur due to mathematical rounding during addition.

THE THREE SEGMENTS OF DERMAPHARM HOLDING SE (INTEGRATED BUSINESS MODEL)



Branded pharmaceuticals

The segment comprises around 400 pharmaceutical active ingredients, resulting in over 1,400 national and international drug approvals. The range of medicinal products, medical devices and food supplements is specialised in selected therapeutic areas in which Dermapharm occupies a leading market position, particularly in Germany.

Other healthcare products

In the “Other healthcare products” segment, Dermapharm mainly combines herbal extracts, nutritional supplements, herbal medicinal products and cosmetics as well as medical devices. In addition to the French company Arkopharma, the market leader for phytotherapeutic dietary supplements in France, the segment also includes the Spanish company Euromed S.A., a leading global manufacturer of plant extracts and herbal active ingredients for the pharmaceutical, nutraceutical, food, and cosmetics industries.




Parallel import business

Dermapharm’s business model also includes a “Parallel import business” segment, which is operated under the “axicorp” brand. Based on turnover, axicorp is the seventh-largest parallel importer in Germany in 2025.

REVENUE BY SEGMENTS

ADJUSTED EBITDA BY SEGMENTS

ADJUSTED EBITDA MARGIN



2026 GUIDANCE:

Group Revenue **EUR 1,182 million to EUR 1,218 million** vs. previous year (EUR 1,165.0 million)

Adjusted Group EBITDA **EUR 331 million to EUR 341 million** vs. previous year (EUR 324.8 million)

Legend: Branded pharmaceuticals (blue), Other healthcare product (green), Parallel import business (teal), Total (grey)

As of 1 August 2025, Solaris Pharma will be reported in the ‘Branded Pharmaceuticals’ segment, and as of 1 October 2025, F. Trenka will be included in this segment as well. Hübner Naturarzneimittel GmbH (until 31 December 2024 reported under ‘Other Healthcare Products’) was retroactively merged into mibe GmbH Arzneimittel (‘Branded Pharmaceuticals’) effective 1 January 2025. For comparability purposes, the prior-year figures have been retrospectively adjusted.